RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

[News]

Castrate-refractory prostate cancer, which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy.

More... (http://www.news-medical.net/news/20100423/RMEI-PIM-jointly-sponsor-complimentary-continuing-education-virtual-lecture-on-CRPC.aspx)